Riskpilot← Back to searchSign inGet full accessEPS Vascular Oy
OYActiveY-tunnus 2880517-7Hauralantie 43Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20183 employeeswww.epsvascular.com
Revenue 2024
EUR 7,5M
+31% vs 2023
EBITDA margin
9.3%
+12% vs 2023
Equity ratio
52.6%
Financial strength
Net profit 2024
EUR 553K
+11% vs 2023
| Revenue | EUR 7,5M | +31% |
| EBITDA | EUR 700K | +12% |
| Net profit | EUR 553K | +11% |
| Total assets | EUR 2,4M | +15% |
| Equity | EUR 1,3M | +4% |
| Employees | 3 | — |
Legal name
EPS Vascular Oy
Y-tunnus number
2880517-7
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5. tammikuuta 2018
Share capital
EUR 2 500
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Bolagets verksamhetsområde är att bedriva distribution av medicintekniska produkter inom hjärtkärl-, neuro- och perifera områden.
Address
Hauralantie 43
Email
info.fi@epsvascular.com
Website
www.epsvascular.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 571 | 4 338 | 4 775 | 5 723 | 7 517 |
| Staff expenses | −373 | −439 | −463 | −1 003 | −683 |
| EBITDA | 431 | 574 | 348 | 625 | 700 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 431 | 574 | 348 | 625 | 700 |
| Net financials | −14 | −8 | −0 | 0 | 0 |
| Profit before tax | 417 | 566 | 348 | 625 | 700 |
| Tax | 86 | 114 | 72 | 128 | 147 |
| Net profit | 331 | 452 | 276 | 497 | 553 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 329 | 1 794 | 1 924 | 2 134 | 2 447 |
| Equity | 510 | 962 | 1 237 | 1 234 | 1 287 |
| Long-term debt | 37 | 114 | 80 | 0 | 0 |
| Short-term debt | 781 | 719 | 606 | 1 | 1 |
| Total debt | 819 | 832 | 687 | 900 | 1 160 |
EBITDA margin
9.3%
This company
15.8%
Market median
-41% vs market
20202024
Equity ratio
52.6%
This company
38.2%
Market median
+38% vs market
20202024
Return on equity
43.0%
This company
18.4%
Market median
+134% vs market
20202024
Net profit margin
7.4%
This company
8.1%
Market median
-9% vs market
20202024
Asset turnover
3.07×
This company
1.12×
Market median
+174% vs market
20202024
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PR Chief Executive Officer | Chief Executive Officer | 2018 |
| Former (2) | ||
LJ | Audit | 2018 – 2021 |
RT Audit | Audit | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairperson | 2019 | |
| Former (3) | ||
| Board of Directors | 2019 – 2023 | |
| Board of Directors | 2018 – 2023 | |
| Board of Directors | 2019 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EPS Vascular Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lauri Janne Ilmari Mäki | Audit | 0 companies |
| Pasi Robert Loukiainen | Chief Executive Officer | 0 companies |
| Risto Tapani Mäkinen | Audit | 0 companies |
| Set Joakim Eriksson | Board of Directors | 0 companies |
| Curt-Jörgen Per Petersson | Board of Directors | 0 companies |
| Siobhan Brigid Taaffe | Board of Directors | 0 companies |
| Timothy Dolphin | Chairperson | 0 companies |
| Padraic William Dempsey | Board of Directors | 0 companies |